Observational studyScientific reports2025
A correlational study of plasma galectin-3 as a potential predictive marker of postoperative delirium in patients with acute aortic dissection.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aimed to demonstrate whether plasma galectin-3 could predict the development of postoperative delirium (POD) in patients with acute aortic dissection (AAD). Prospective, observational study. Cardiac surgery intensive care unit. Consecutive patients who were diagnosed with AAD and operated at the Cardiac Medical Center of Fujian Province between December 2020 and December 2022. Patients were classiffed into two groups according to the Confusion Assessment Method for the Intensive Care Unit: POD group and NON-POD group. Each patient's plasma was tested before emergency surgery. Baseline demographic data and preoperative, intraoperative, and postoperative clinical data were collected. The short-term clinical outcomes were followed up daily. The rate of POD was calculated. The risk factors for POD were analyzed through univariate analysis and multivariate logistic regression. Receiver operating characteristic (ROC) curves were used to assess the ability of plasma galectin-3 to predict POD. A total of 309 study subjects were included in this study, and the rate of POD was 38.8%. Patients with AAD were categorized into the POD and NON-POD cohorts postoperatively based on their CAM-ICU scores. There was no statistically significant difference in the baseline characteristics between the two groups (P > 0.05). However, patients in the POD group had significantly elevated plasma galectin-3 levels (P < 0.001). The ROC curves showed that plasma galectin-3 had a sensitivity of 72.5% and a specificity of 70.9% as a potential biomarker for the diagnosis of POD. The critical value of plasma galectin-3 for diagnosing POD was 9.18 ng/mL. Plasma galectin-3 levels remained an independent predictor of POD after controlling for different variables (P < 0.001). Elevated plasma galectin-3 levels are associated with an increased risk of POD. Plasma galectin-3 may be a prospective biomarker for predicting POD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.